Sunnyvale, CA, United States of America

Tomasz W Glinka


Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 1997-2000

Loading Chart...
12 patents (USPTO):

Title: Inventor Profile: Tomasz W. Glinka

Introduction

Tomasz W. Glinka is a prominent inventor based in Sunnyvale, California, recognized for his significant contributions to the field of antibiotics. Holding a total of 12 patents, Glinka's work primarily focuses on the development of novel cephalosporin antibiotics that target a broad spectrum of bacterial organisms, including those resistant to traditional beta-lactam antibiotics.

Latest Patents

Among Glinka's latest innovations are two notable patents concerning cephalosporin antibiotics. These inventions include novel compounds with specific structural formulas designed to exhibit antibiotic activity against resistant organisms. The compounds also provide pharmacologically acceptable salts and introduce novel intermediates essential for the production of these innovative antibiotics. The methodologies presented in these patents are aimed at enhancing the production and efficacy of antibacterial agents in the current medical landscape.

Career Highlights

Currently, Tomasz W. Glinka is associated with Microcide Pharmaceuticals, Inc., a company dedicated to advancing antibacterial therapies. His extensive experience is reflected in his multiple patents that showcase his commitment to addressing critical healthcare challenges through innovative solutions.

Collaborations

Glinka has collaborated with notable colleagues in his career, including Scott J. Hecker and In-Seop Cho. Their joint efforts in research and development have contributed to significant advancements in the field of pharmaceutical sciences, particularly in creating effective treatments against bacterial infections.

Conclusion

Tomasz W. Glinka stands out as a talented inventor in the pharmaceutical industry, particularly for his contributions to cephalosporin antibiotics. His dedication to innovation and collaboration continues to pave the way for new developments in antibiotic treatments, addressing the pressing issue of antibiotic resistance in modern medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…